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Objective: ​Hypoglycemia is a common complication of tighter glucose control regimens in type             
2 diabetes (T2D) and may increase risk of Alzheimer’s disease (AD). We hypothesized that              
changes in amyloid-related protein levels during induced hypoglycemia would be exacerbated           
during/following hypoglycemia in type 2 diabetes (T2D).  
Methods: ​A prospective, parallel study in T2D (n=23) and controls (n=23). Hypoglycemia            
(<2.2mmol/l; <40mg/dl) was achieved by intravenous insulin infusion. Blood sampling was           
performed at baseline, hypoglycemia and post-hypoglycemia; proteomic (Somalogic) analysis of          
amyloid-related proteins performed: Amyloid-precursor protein [APP], Amyloid P-component        
[APCS], Noggin, Alpha-synuclein [SNCA], Microtubule-associated protein tau [MAPT],        
Pappalysin [PAPPA], Serum amyloid-A1 [SAA1], Apolipoprotein-A1 [ApoA1] and        
Apolipoprotein-E3 [ApoE3]. 
Results: APP was elevated (p<0.01) at baseline in T2D while SNCA was reduced (p<0.01). At               
hypoglycemia, APCS (p<0.01) was elevated and SNCA (p<0.05) reduced in T2D, whilst APP             
(p<0.01) and Noggin (p<0.05) were elevated and SNCA (p<0.01) reduced in controls. Following             
hypoglycemia, APP and MAPT normalized in controls but decreased below baseline in T2D;             
Noggin normalized in both cohorts; SNCA normalized in T2D but decreased below baseline in              




Conclusions: Baseline parameters showed an increase in APP and a reduction in SNCA in T2D,               
reflecting the baseline levels previously reported in AD; these baseline changes were            
exaggerated, with APP increase and SNCA decrease, in response to hypoglycemia seen in both              
T2D and controls. Hypoglycemia was associated with changes in AD-associated proteins of            
APCS, MAPT, ApoA1, ApoE3 and PAPPA in T2D only, and Noggin in both cohorts.  
 




Type 2 diabetes (T2D) prevalence has reached pandemic proportions. The International Diabetes            
Federation (IDF) currently estimates that approximately 425 million individuals worldwide have           
diabetes​ ​(1), a figure projected to rise to 642 million by the year 2040. 
In addition to classical macro- and microvascular complications of diabetes, dementia is a             
recognized association (2). The risk of dementia in individuals with T2D is strikingly increased              
(50-150%) relative to the general population (3-6). Predictions suggest that the worldwide            
prevalence of patients suffering from dementia will increase from 35.6 million in 2010 to 115.4               
million in 2050 (7). Given the association between T2D and dementia, and the dramatic              
predicted increases in each disease individually, the combined effect may exceed these            
predictions and have an even more devastating effect on the global population.  
Alzheimer’s disease (AD) comprises 60-80% of all dementia cases (8). Epidemiological studies            
have shown an increased risk for subjects with T2D developing AD (9-11). Elevation in plasma               




increase with increasing cognitive impairment (12, 13). Whilst no difference in plasma levels of              
alpha-synuclein (SNCA) had previously been reported (14), a recent study showed lower            
concentrations of SNCA in red blood cells in the circulation of AD subjects (15). 
Improved management of T2D involves stricter glucose control, increasing the risk and            
frequency of hypoglycemic episodes. Hypoglycemia itself is directly linked to cognitive           
dysfunction, complicating diabetic management and perhaps increasing the risk of dementia           
(16). 
We hypothesized that changes in amyloid-related protein levels during induced hypoglycemia           
would be exacerbated during/following hypoglycemia in type 2 diabetes (T2D), thus providing a             
potential mechanistic link between T2D-related hypoglycemia and AD. This study was           
specifically designed to mimic the physiological responses to hypoglycemia as would be seen in              
diabetic patients in clinical practice (17). To this end, we analyzed the levels of amyloid-related               
proteins following acute iatrogenic induction of hypoglycemia in subjects with and without T2D.  
 
Materials and Methods  
A prospective parallel study was performed in the Diabetes Research Centre at Hull Royal              
Infirmary in adult T2D (n=23) and control (n=23) subjects between November 2011 and May              
2013. All participants provided written informed consent. The trial was approved by the North              
West-Greater Manchester East Research Ethics Committee (REC number:16/NW/0518),        
registered at www.clinicaltrials.gov (NCT03102801) and conducted according to the Declaration          
of Helsinki.  
All participants were Caucasian, aged 40-70 years. For T2D, diabetes duration was <10 years; all               
were on a stable dose of medication (metformin, statin and/or angiotensin converting enzyme             




cohort: any medications for glycemic control except metformin; poor glycemic control [HbA1c            
levels ≥10% (86mmol/mol)]; hypoglycemic unawareness or history of severe hypoglycemia in           
previous 3 months. Exclusion criteria for control group: diagnosis of type 1 or 2 diabetes or                
HbA1c >6% (42mmol/mol). Exclusion criteria for both groups: body mass index (BMI)<18 or             
>50kg/m​2​; excessive alcohol consumption; renal or liver disease; history or presence of            
malignant neoplasms within prior 5 years; psychiatric illness; history of acute or chronic             
pancreatitis or gastrointestinal tract surgery; steroid treatment; pregnant or breastfeeding women;           
any contraindication to insulin infusion to achieve hypoglycemia (ischemic heart disease,           
epilepsy, history of seizures, drop attacks, history of adrenal insufficiency and treated            
hypothyroidism).  
Participants were screened by medical history, clinical examination, routine blood tests and an             
electrocardiogram. On the day of the study, participants avoided habitual exercise (defined as             
brisk walking >20min) for >24h and individuals with T2D on medication withheld their oral              
hypoglycemic agents on the morning of the visit. Participants were weighed (Marsden Weighing             
Machine Group Ltd, UK) and height was taken barefoot using a wall-mounted stadiometer.             
Blood pressure was measured using a sphygmomanometer (Datascope Duo Masimo Set,           
Mindray Ltd, UK) and a fasting blood sample was collected before insulin infusion (baseline). A               
continuous insulin infusion was performed to induce hypoglycemia. Blood samples were taken at             
0, 30, 60, 120 and 240 minutes after hypoglycemia. After 240 minutes, participants were              
provided lunch and were given their (morning) diabetes medications. Patients took their evening             
medication as prescribed that day. Subjects reattended 24-hours following the induction of            
hypoglycemia; patients withheld their medications until they completed the blood tests in the             





using a glucose analyser (HemoCue® glucose 201+) to ensure normal levels, together with other              
vital signs.  
Insulin Infusion  
Following an overnight fast, bilateral ante-cubital fossa indwelling cannulas were inserted 30-60            
minutes prior to the commencement of the test (0830h). To induce hypoglycemia, soluble             
intravenous insulin (Humulin S, Lilly, UK) was given in a pump starting at a dose of 2.5mU/kg                 
body weight/min with an increment of 2.5mU/kg body weight/min every 15min by            
hypoglycemic clamp (18), until two readings of capillary blood glucose measured by a glucose              
analyser (HemoCue® glucose 201+) ≤2.2 mmol/L (<40mg/dl) or a reading of ≤2.0 mmol/L             
(36mg/dl) (18). The blood sample schedule was timed subsequently in respect to the time point               
that hypoglycemia occurred. Following the identification of hypoglycemia, intravenous glucose          
was given in the form of 150 ml of 10% dextrose and a repeat blood glucose check was                  
performed after 5 minutes if blood glucose was still <4.0 mmol/L.  
Biochemical markers: 
Blood samples were separated immediately by centrifugation at 2000g for 15 minutes at 4°C,              
and the aliquots were stored at –80°C, within 30 minutes of blood collection, until batch               
analysis. Fasting plasma glucose (FPG), total cholesterol, triglycerides, and high-density          
lipoprotein (HDL) cholesterol levels were measured enzymatically using a Beckman AU           
5800 analyser (Beckman-Coulter, High Wycombe, UK) 
SOMA-scan assay 
The SOMAscan assay used to quantify proteins was performed on an in-house Tecan Freedom              
EVO liquid handling system (Tecan Group, Maennedorf, Switzerland) utilizing buffers and           




according to manufacturer’s instructions and as described previously (19, 20). The assay was             
performed in 96-well plates containing up to 85 plasma samples, 3 quality control and 5               
calibrator plasma samples. Briefly, EDTA plasma samples were diluted into bins of 40%, 1%              
and 0.05% and incubated with streptavidin-coated beads immobilized with dilution-specific          
SOMAmers via a photocleavable linker and biotin. After washing bound proteins were first             
biotinylated and then released from beads by photocleaving the SOMAmer-bead linker. The            
released SOMAmer-protein complex was treated with a polyanionic competitor to disrupt           
unspecific interactions and recaptured on a second set of streptavidin-coated beads. Thorough            
washing was performed before 5’ Cy3 fluorophore labelled SOMAmers were released under            
denaturing conditions, hybridized on microarray chips with SOMAmer-complementary        
sequences, and scanned using the SureScan G2565 Microarray Scanner (Agilent, Santa Clara,            
CA).  
Data processing and analysis 
Initial Relative Fluorescent Units (RFUs) were obtained from microarray intensity images using            
the Agilent Feature Extraction Software (Agilent, Santa Clara, CA). Raw RFUs were normalized             
and calibrated using the software pipeline provided by SomaLogic. This included (a) microarray             
hybridization normalization based on spiked-in hybridization controls, (b) plate-specific intensity          
normalization, (c) median signal normalization, and (d) median calibrator scaling of single RFU             
intensities according to calibrator reference values. Samples with high degree of hemolysis            
(Haptoglobin log RFU < 10) were excluded from analysis. 
Statistical analyses were performed on log​2 RFU values using R version 3.5.2 (R Foundation for               
Statistical Computing, Vienna, Austria) including base R package. Data handling and differential            




differential protein analysis we applied limma models containing contrasts between timepoints,           
as well as contrasts between healthy and diabetic patients at single timepoints. In both models,               
blocking by patient ID was performed to account for random effects. Batch effect correction was               
performed by adding batch as covariate to the model. Limma obtained P values were corrected               
using the Benjamini-Hochberg method (22). 
Statistical analysis: 
Data trends were visually evaluated for each parameter and non-parametric tests were applied on              
data that violated the assumptions of normality when tested using the Kolmogorov-Smirnov            
Test. Comparison between groups was performed at each timepoint using Student’s t-test. A             
p-value of <0.05 was considered statistically significant. Within group comparisons are as            
follows: changes from baseline, and from hypoglycemia, to each subsequent timepoint were            
compared using Student’s t-test. The sample size was too small to adjust for baseline covariates.               
Statistical analysis was performed using Graphpad Prism (San Diego, CA, USA). 
For the proteomic analysis we fitted an intercept-free general linear model as a function of               
subgroup (i.e. condition:timepoint), while taking the patient ID as a random effect using the R               
package limma. Subsequently, we computed the p value for two contrasts: baseline to             
hypoglycemia for both T2D and controls, and false discovery rate (FDR) corrected at a value of                
<0.05 as the cutoff for significance.  
 
Results:  
46 subjects were recruited (23 people with T2D, 23 controls)(17). Demographic and clinical             




Nine amyloid-related proteins were included in the analysis: Amyloid precursor protein [APP],            
Amyloid P component [APCS], Noggin, Alpha-synuclein [SNCA], Microtubule-associated        
protein tau [MAPT], Pappalysin [PAPPA] and Serum amyloid A1 [SAA1], Apolipoprotein A1            
[ApoA1] and Apolipoprotein E3 [ApoE3]. 
 
Differences between T2D and controls 
In the T2D cohort, baseline levels of APP were elevated (35594±6559 vs 18535±1837 RFU, 
T2D vs control, p<0.01) (Figure 1A) and SNCA decreased (5836±272 vs 7175±420 RFU, T2D 
vs control, p<0.01) (Figure 1B). Baseline levels of the other proteins did not differ between 
cohorts (Figure 2A – 2D) and (Figure 3A – 3D).  
At hypoglycemia, APCS was elevated in T2D (35128±1307 vs 31594±1473 RFU, T2D vs 
control, p<0.05) (Figure 2B)​. 
 
Within cohort changes at the point of hypoglycemia 
Significant changes occurred in the control group in response to hypoglycemia with APP and              
Noggin being elevated (Control, hypoglycemia vs baseline: APP, 37549±7046 vs 18535±1837           
RFU, p<0.01) (Figure 1A); Noggin, 2899±344 vs 2084±123 RFU, p<0.05) (Figure 2C) and             
SNCA levels decreasing (Control, hypoglycemia vs baseline: 5558±310 vs 7175±420 RFU,           
p<0.01) (Figure 1B). 
In the T2D cohort, APP levels were already elevated as compared to controls, so whilst there was                 
a further increase in response to hypoglycemia, this did not reach significance. Whilst SNCA              




depressed in T2D in response to hypoglycemia (T2D, hypoglycemia vs baseline:           
alpha-synuclein, 4931±261 vs 5836±272 RFU, p<0.05) (Figure 1B).  
 
Changes in protein levels in the 24-hour follow-up period 
In the post-hypoglycemia period, the elevated hypoglycemia-induced APP levels gradually          
decreased to baseline during the 24-hour follow-up period in controls (Controls: 30-minutes vs             
hypoglycemia, 21714±4539 vs 37549±7046 RFU, p<0.05; 1-hour vs hypoglycemia, 18994±3077          
vs 37549±7046 RFU, p<0.01; 2-hour vs hypoglycemia, 17905±4890 vs 37549±7046 RFU,           
p<0.05; 4-hour vs hypoglycemia, 17475±3219 vs 37549±7046 RFU, p<0.01; 24-hour vs           
hypoglycemia, 16237±2788 vs 37549±7046 RFU, p<0.01). In T2D, APP levels were depressed            
below baseline levels in the follow-up period (T2D: 30-minutes vs hypoglycemia, 30455±5064            
vs 46877±6340 RFU, p<0.05; 1-hour vs hypoglycemia, 30507±5665 vs 46877±6340 RFU,           
p<0.05; 2-hour vs hypoglycemia, 26690±6211 vs 46877±6340 RFU, p<0.05; 4-hour vs           
hypoglycemia, 20684±3780 vs 46877±6340 RFU, p<0.001; 24-hour vs hypoglycemia,         
21728±3955 vs 46877±6340 RFU, p<0.001) (Figure 1A).  
Following a hypoglycemia-induced decrease in SNCA, levels normalized to baseline in the T2D             
cohort. In the control group, however, levels continued to decrease further during the follow-up              
period relative to baseline (Control: 30-minutes vs baseline, 4944±223 vs 7175±420 RFU,            
p<0.0001; 1-hour vs hypoglycemia, 5170±284 vs 7175±420 RFU, p=0.0001; 2-hour vs           
hypoglycemia, 5196±340 vs 7175±420 RFU, p<0.001; 4-hour vs hypoglycemia, 5089±460 vs           





In both cohorts, MAPT (tau) levels showed a non-significant increasing trend in response to              
hypoglycemia that, in controls, normalized to baseline in the follow-up period. In T2D, the              
MAPT level decreased below baseline in the follow-up period (T2D: 30-minutes vs            
hypoglycemia, 147±7 vs 166±10 RFU, p=ns; 1-hour vs hypoglycemia, 143±7 vs 166±10 RFU,             
p<0.05; 2-hour vs hypoglycemia, 130±9 vs 166±10 RFU, p<0.01; 4-hour vs hypoglycemia,            
132±5 vs 166±10 RFU, p<0.01; 24-hour vs hypoglycemia, 136±6 vs 166±10 RFU, p<0.01)             
(Figure 2A). 
APCS levels were unchanged in the control group and largely unchanged in the T2D cohort, with                
only the 2-hour timepoint being decreased relative to hypoglycemia (T2D: 2-hour vs            
hypoglycemia, 31589±1394 vs 35128±1307, p<0.05) (Figure 2B). 
Hypoglycemia-induced elevations in Noggin also returned to baseline in both the control and             
T2D cohorts during the follow-up period (Control: 30-minutes vs hypoglycemia, 2121±171 vs            
2899±344 RFU, p<0.05; 1-hour vs hypoglycemia, 2162±203 vs 2899±344 RFU, p<0.05; 2-hour            
vs hypoglycemia, 1896±198 vs 2899±344 RFU, p<0.01; 4-hour vs hypoglycemia, 1809±104 vs            
2899±344 RFU, p<0.01; 24-hour vs hypoglycemia, 2017±143 vs 2899±344 RFU, p<0.05) (T2D:            
30-minutes vs hypoglycemia, 2383±243 vs 2788±228 RFU, p=ns; 1-hour vs hypoglycemia,           
2236±221 vs 2788±228 RFU, p<0.05; 2-hour vs hypoglycemia, 2058±283 vs 2788±228 RFU,            
p<0.05; 4-hour vs hypoglycemia, 1974±188 vs 2788±228 RFU, p<0.001; 24-hour vs           
hypoglycemia, 2048±157 vs 2788±228 RFU, p<0.001) ​(​Figure 2C). 
PAPPA ​was unchanged during the study in the control subjects; in the T2D subjects, PAPPA               
tended to increase in the follow-up period relative to baseline, specifically at the 30-minute and               
4-hour timepoints (T2D: 30-minutes vs baseline, 18299±1129 vs 15260±973 RFU, p<0.05;           




14907±1000 vs 15260±973 RFU, p=ns; 4-hour vs hypoglycemia, 18246±1301 vs 15260±973           
RFU, p<0.05; 24-hour vs hypoglycemia, 16498±1000 vs 15260±973 RFU, p=ns) (Figure 2D). 
 
SAA1 levels did not change during the study in either cohort (Figure 3A).  
ApoA1, a protein central to the interaction network of APCS, APP and SAA1, was unchanged at                
hypoglycemia or at any time-point in the 24-hour follow-up period in control subjects; in the               
T2D subjects, the level of ApoA1 trended downwards in the follow-up period, reaching             
significance at 24-hours (T2D: 24-hours vs hypoglycemia, 11426±417 vs 12780±397 RFU,           
p<0.05) (Figure 3B). 
ApoE3 levels were raised at 4-hours post-hypoglycemia in the T2D cohort only (T2D: 4-hours vs               
baseline, 173319±12097 vs 143355±10655 RFU, p<0.05; 4-hours vs hypoglycemia,         
173319±12097 vs 142301±11440 RFU, p<0.05) (Figure 3C).  
ApoE4 levels were no different between control and T2D subjects and remained unchanged             
throughout the study (Figure 3D). 
The string network interaction (STRING version 11.0) revealed that plasma AD-related proteins 
(APCS, APP, SAA1 and APOA1, MAPT and APP and PAPPA) that showed differences in 
response to hypoglycemia are interconnected, suggesting linkage between hypoglycemia and 
induction of AD in T2D (Figure 4A–C). 
Moreover, Ingenuity Pathway Analysis of the AD-related proteins also revealed the possible 
cellular pathways and mechanistic linkage of 4 proteins (APCS, APP, PAPPA, SAA1) in 






There have been no previous studies looking at Alzheimers-related proteins in plasma in             
response to hypoglycemia. Here, we show changes in plasma Alzheimer-related proteins in            
response to iatrogenic-induced hypoglycemia in T2D and control subjects. Basal APP was higher             
and SNCA was lower in T2D, a pattern reflecting those findings reported for basal levels in AD                 
(12, 13, 15). These changes were also observed in the post-hypoglycemia period for T2D and               
control subjects, with an elevation of APP that subsequently and significantly reduced in both              
controls and T2D, whilst SNCA significantly reduced in both controls and T2D following             
hypoglycemia, indicating that hypoglycemia induced further changes of these AD related           
proteins. Similarly, Noggin appeared to be increased by hypoglycemia, then fell significantly            
afterwards to baseline levels. The AD related proteins MAPT, PAPPA, ApoA1 and ApoE3             
remained unchanged in controls whilst, in T2D, MAPT and ApoA1 were reduced following             
hypoglycemia but returned to baseline levels whilst PAPPA and ApoE3 increased in response to              
hypoglycemia over the following 4-hour time course but returned to baseline at 24 hours. Some               
proteins, such as SAA1, remained unchanged throughout the study period in both cohorts. 
  
AD and T2D are both diseases characterized by increased prevalence with aging, genetic             
predisposition and comparable pathological features of amyloid deposition in brain (23-26) and            
pancreatic islets (27, 28), respectively. The pathogenesis of amyloid diseases involving, for            
example, hippocampal cells in Alzheimer’s disease, dopaminergic neurons in Parkinson’s          
disease and beta-cells in type 2 diabetes, involves abnormal interactions of amyloidogenic            
proteins with cellular machinery and membranes (29). Thus, these diverse conditions are all             
considered to be diseases of protein misfolding (30-32). Much evidence points to the prefibrillar              




AD is characterized by accumulation of ​β​-amyloid (A​β​) and tau proteins in the brain. Evidence               
points to the generation of A​β from amyloid precursor protein (APP) as the critical step in                
development of AD (37) and elevated serum levels have been reported (12, 13), as are reported                
here.  
Amyloid P component (APCS) has been found in the senile plaques and neurofibrillary tangles              
in the brain of subjects with Alzheimer’s disease (38) and may hinder proteolysis of A​β deposits,                
thereby promoting plaque formation (39); serum levels have been reported to be decreased (38),              
in accord with our findings in the current study.  
Alpha-synuclein induces the fibrillization of MAPT (tau); while mostly associated with the            
pathophysiology of synucleinopathies such as Parkinson’s disease and Lewy body-associated          
dementia, it is also involved in Alzheimer’s disease-related brain pathology through its            
interactions with A​β​ (40).  
Tau is a microtubule-associated protein in neurons encoded by the ​MAPT gene; in tauopathies,              
aberrant assembly and deposition of tau is accompanied by synaptic dysfunction and death of              
neurons (41) and increases in plasma tau have been associated with AD (42). In this study, there                 
was a transient increase in MAPT (tau) levels in response to hypoglycemia, with levels in the                
follow-up period returning to baseline.  
Pappalysins (PAPPAs) are known to cleave IGF-binding proteins (IGFBPs), and overexpression           
of PAPPA-2 has been shown to play a role in Aβ peptide accumulation in Alzheimer’s disease                
(43). Increased serum levels of PAPPA-1 have been reported in T2D subjects (44) and this is in                 
accord with their suggested shared pathophysiology (45). Elevated levels of PAPPA were only             
seen in patients with T2D following the hypoglycemic event and were increased for to up to 4                 




Studies are inconclusive as regards circulating ApoE levels in AD (46), with some reporting an               
increase (47), some a decrease (48) and some no change (49). In this study, we found an increase                  
in ApoE3 levels in T2D following hypoglycemia and lasting until the 4-hour timepoint, but with               
no change in controls. ApoE and ApoE4 levels were unchanged throughout the study in either               
cohort.  
Higher circulating ApoA1 levels are associated with a lower risk of AD (50) and dementia (51).                
In this study, ApoA1 showed an overall decrease, still present at 24-hours, following             
hypoglycemia in T2D but not in controls.  
Serum amyloid A1 (SAA1) is an acute phase protein that may play a housekeeping role in                
normal tissue, but increased expression has been shown in the brain in Alzheimer’s disease (52).               
There were no changes in SAA in either the controls or T2D in response to hypoglycemia.  
That so many of the proteins changed in response to induced hypoglycemia is not surprising               
given the interrelated protein interactions shown clearly in the string analysis that were in accord               
with other reports (12, 13, 38, 42, 44, 50); however, the differential effect of the protein response                 
in T2D compared to controls was marked. 
Taken together, these results suggest that an AD pattern of proteins may be seen at baseline for                 
patients with T2D; hypoglycemia causes their enhanced expression that may lead to an             
accelerated development of AD in susceptible patients or perhaps those particularly prone to             
severe and recurrent hypoglycemia, as hypoglycemia has been associated with AD (16). What is              
of potential concern is that the patients with T2D in this study had a relatively short duration of                  
disease (less than 5 years) and they were all on single therapy (metformin) that is not associated                 




Repetition of this study in patients of longer diabetes duration or on hypoglycemic agents              
including insulin may show an even greater differential in AD protein expression.  
 
The strengths of this study include the inclusion of a group of T2D subjects of short disease                 
duration who were relatively treatment naïve and not on polypharmacy. The main study             
limitation is the small study numbers and, with a larger population, even greater differences in               
serum levels of amyloid-related proteins may have been discerned. However, it is important to              
note that these patients were subject to a severe hypoglycemic episode, during which it would be                
anticipated that changes in protein levels would have become apparent. Whilst subjects with T2D              
were older and more obese, this should not have altered the expression of these proteins. 
In conclusion, at baseline, T2D subjects had elevated APP and reduced SNCA levels in plasma,               
reflecting the changes previously reported in AD. These baseline changes were exacerbated in             
response to induced hypoglycemia with an increase in APP and a decrease in SNCA seen in both                 
T2D and controls. The other measured proteins did not differ at baseline between the T2D and                
control cohorts. In the post-hypoglycemia period, APCS, MAPT and ApoA1 decreased, and            
ApoE3 and PAPPA increased in T2D only, whilst Noggin levels decreased in both cohorts, and               
SAA levels remained unchanged. Taken together, the circulating protein levels reported here            
suggest that T2D subjects have an increased risk for development of AD, and this risk may be                 






Ethics approval and consent to participate: The trial was approved by the North West-Greater              
Manchester East Research Ethics Committee (REC number:16/NW/0518), registered at         
www.clinicaltrials.gov (NCT03102801) and conducted according to the Declaration of Helsinki.  
All participants provided written informed consent. 
Availability of data and materials: All the data for this study will be made available upon                
reasonable request to the corresponding author. 
Conflict of interest:​ None of the authors have any conflict of interest to declare. 
Funding:​ No funding was received to undertake this work. 
 
Author contributions: ​ASMM - analyzed the data and wrote the manuscript. ​JG– performed             
experiments and contributed to the writing of manuscript; TS– supervised clinical studies and             
data collection and contributed to the writing of manuscript; SLA– contributed to study design,              
data interpretation and the writing of the manuscript. AEB- analyzed the data and wrote the               
manuscript. All authors approved the final version of the manuscript. 
Acknowledgments: The authors declare that there is no conflict of interest that could be perceived               
as prejudicing the impartiality of the paper reported. SLA is the guarantor of this work and, as                 
such, had full access to all the data in the study and takes responsibility for the integrity of the                   
data and the accuracy of the data analysis. No funding was received for doing this work.  
We thank Prof Simon Heller and his team, at the University of Sheffield, for help in development                 
of the hyperinsulinaemic hypoglycaemic clamp protocol. We thank the research nurses at the             








1. DF Diabetes Atlas Belgium: International Diabetes Federation; 2017 [8th:[Available 
from: ttp://​www.diabetesatlas.org​. 
2. Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 
2 diabetes mellitus in the elderly. Nat Rev Endocrinol. 2011;7(2):108-14. 
3. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in 
diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74. 
4. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in 
diabetes--systematic overview of prospective observational studies. Diabetologia. 
2005;48(12):2460-9. 
5. Strachan MW, Deary IJ, Ewing FM, Frier BM. Is type II diabetes associated with an 
increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care. 
1997;20(3):438-45. 
6. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A 
meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4(6):640-50. 
7. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of 
dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75 e2. 
8. Alzheimer's A. 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 
2014;10(2):e47-92. 
9. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and 
the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9):1937-42. 
10. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer 
disease pathology? Nat Rev Neurol. 2010;6(10):551-9. 
11. Zilkens RR, Davis WA, Spilsbury K, Semmens JB, Bruce DG. Earlier age of dementia onset 
and shorter survival times in dementia patients with diabetes. Am J Epidemiol. 
2013;177(11):1246-54. 
12. Yun SM, Cho SJ, Jo C, Park MH, Han C, Koh YH. Elevation of plasma soluble amyloid 
precursor protein beta in Alzheimer's disease. Arch Gerontol Geriatr. 2020;87:103995. 
13. Bush AI, Beyreuther K, Masters CL. Beta A4 amyloid protein and its precursor in 
Alzheimer's disease. Pharmacol Ther. 1992;56(1):97-117. 
14. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, et al. Significance and 
confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 
2010;480(1):78-82. 
15. Baldacci F, Daniele S, Piccarducci R, Giampietri L, Pietrobono D, Giorgi FS, et al. Potential 
Diagnostic Value of Red Blood Cells alpha-Synuclein Heteroaggregates in Alzheimer's Disease. 
Mol Neurobiol. 2019;56(9):6451-9. 
16. Chin SO, Rhee SY, Chon S, Baik SH, Park Y, Nam MS, et al. Hypoglycemia is associated 
with dementia in elderly patients with type 2 diabetes mellitus: An analysis based on the Korea 
National Diabetes Program Cohort. Diabetes Res Clin Pract. 2016;122:54-61. 
17. Al-Qaissi A, Papageorgiou M, Deshmukh H, Madden LA, Rigby A, Kilpatrick ES, et al. 
Effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and 




18. Hepburn DA, Frier BM. Hypoglycemia Unawareness in Patients with Insulin-Treated 
Diabetes-Mellitus. Saudi Medical Journal. 1991;12(3):182-90. 
19. Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, Keeney TR, et al. From SOMAmer-based 
biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined 
multiplex proteomic assay. PLoS One. 2011;6(10):e26332. 
20. Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, et al. Connecting 
genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 
2017;8:14357. 
21. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential 
expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 
2015;43(7):e47. 
22. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in 
behavior genetics research. Behav Brain Res. 2001;125(1-2):279-84. 
23. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid 
plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 
1985;82(12):4245-9. 
24. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal 
origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same 
protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4(11):2757-63. 
25. Bahmanyar S, Higgins GA, Goldgaber D, Lewis DA, Morrison JH, Wilson MC, et al. 
Localization of amyloid beta protein messenger RNA in brains from patients with Alzheimer's 
disease. Science. 1987;237(4810):77-80. 
26. Goedert M. Neuronal localization of amyloid beta protein precursor mRNA in normal 
human brain and in Alzheimer's disease. EMBO J. 1987;6(12):3627-32. 
27. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in 
maturity onset diabetes mellitus. Diabetologia. 1978;15(5):417-21. 
28. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and 
increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102-10. 
29. Jayaraman S, Gantz DL, Haupt C, Gursky O. Serum amyloid A forms stable oligomers that 
disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. 
Proc Natl Acad Sci U S A. 2017;114(32):E6507-E15. 
30. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, et al. A 
causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem 
Biol. 2010;6(2):140-7. 
31. Stefani M. Structural features and cytotoxicity of amyloid oligomers: implications in 
Alzheimer's disease and other diseases with amyloid deposits. Prog Neurobiol. 
2012;99(3):226-45. 
32. Guerrero-Munoz MJ, Castillo-Carranza DL, Kayed R. Therapeutic approaches against 
common structural features of toxic oligomers shared by multiple amyloidogenic proteins. 
Biochem Pharmacol. 2014;88(4):468-78. 
33. Hirakura Y, Carreras I, Sipe JD, Kagan BL. Channel formation by serum amyloid A: a 




34. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid 
polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. 
Diabetes. 1999;48(3):491-8. 
35. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common 
structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 
2003;300(5618):486-9. 
36. Gurlo T, Ryazantsev S, Huang CJ, Yeh MW, Reber HA, Hines OJ, et al. Evidence for 
proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form 
intracellularly in the secretory pathway. Am J Pathol. 2010;176(2):861-9. 
37. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. 
Annu Rev Neurosci. 2011;34:185-204. 
38. Nishiyama E, Iwamoto N, Kimura M, Arai H. Serum amyloid P component level in 
Alzheimer's disease. Dementia. 1996;7(5):256-9. 
39. Verwey NA, Schuitemaker A, van der Flier WM, Mulder SD, Mulder C, Hack CE, et al. 
Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's 
disease. Dement Geriatr Cogn Disord. 2008;26(6):522-7. 
40. Twohig D, Nielsen HM. alpha-synuclein in the pathophysiology of Alzheimer's disease. 
Mol Neurodegener. 2019;14(1):23. 
41. Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta 
Neuropathol. 2017;133(5):665-704. 
42. Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, et al. Plasma 
tau in Alzheimer disease. Neurology. 2016;87(17):1827-35. 
43. Mihelcic M, Simic G, Babic Leko M, Lavrac N, Dzeroski S, Smuc T, et al. Using 
redescription mining to relate clinical and biological characteristics of cognitively impaired and 
Alzheimer's disease patients. PLoS One. 2017;12(10):e0187364. 
44. Heidari B, Fotouhi A, Sharifi F, Mohammad K, Pajouhi M, Paydary K, et al. Elevated 
serum levels of pregnancy-associated plasma protein-A in type 2 diabetics compared to healthy 
controls: associations with subclinical atherosclerosis parameters. Acta Med Iran. 
2015;53(7):395-402. 
45. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and 
Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365-76. 
46. Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx. 2004;1(2):226-34. 
47. Taddei K, Clarnette R, Gandy SE, Martins RN. Increased plasma apolipoprotein E (apoE) 
levels in Alzheimer's disease. Neurosci Lett. 1997;223(1):29-32. 
48. Siest G, Bertrand P, Qin B, Herbeth B, Serot JM, Masana L, et al. Apolipoprotein E 
polymorphism and serum concentration in Alzheimer's disease in nine European centres: the 
ApoEurope study. ApoEurope group. Clin Chem Lab Med. 2000;38(8):721-30. 
49. Scacchi R, Gambina G, Ruggeri M, Martini MC, Ferrari G, Silvestri M, et al. Plasma levels 
of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci 
Lett. 1999;259(1):33-6. 
50. Button EB, Robert J, Caffrey TM, Fan J, Zhao W, Wellington CL. HDL from an Alzheimer's 




51. Saczynski JS, White L, Peila RL, Rodriguez BL, Launer LJ. The relation between 
apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am J Epidemiol. 
2007;165(9):985-92. 
52. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a 
major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7(1):64-9. 
Table 1.​ Demographic and clinical characteristics of the study participants. 
 
  
Baseline Type 2 Diabetes 
(n=23) 
Controls (n=23) p-value 
Age (years) 64±8 60±10 <0.0001 
Sex (M/F) 12/11 11/12 0.77 
Weight (kg) 90.9±11.1 79.5±8.8 <0.0001 
Height (cm) 167±14 169±5 0.64 
BMI (kg/m​2​)  32±4 28±3 <0.0001 
Systolic BP (mmHg) 132±8 122±8 0.001 
Diastolic BP (mmHg) 81±7 75±6 0.003 
Duration of diabetes (years) 4.5±2.2 N/A  
HbA1c (mmol/mol) 51.2±11.4 37.2±2.2 <0.0001 
HbA1c (%) 6.8±1.0 5.6±0.2 <0.0001 
Total cholesterol (mmol/l) 4.2±1.01.0 4.8±0.77 0.014 
Triglyceride (mmol/l) 1.7±0.7 1.34±0.6 0.055 
HDL-cholesterol (mmol/l) 1.1±0.3 1.5±0.4 0.001 
LDL-cholesterol (mmol/l) 2.23±0.8 2.7±0.87 0.051 
CRP (mg/l) 3.10±2.87 5.30±1110.03 0.66 
BMI: Body mass index, BP: Blood pressure, HDL-cholesterol: High density lipoprotein           
cholesterol, LDL-cholesterol: Low density lipoprotein cholesterol, CRP: C-reactive protein.         








Figure 1. ​Comparison of Alzheimer-related proteins, Amyloid precursor protein (APP) and           
α-synuclein (SNCA) in plasma before, during and after iatrogenic induction of hypoglycemia.            
Blood sampling was performed at baseline, at hypoglycemia and post-hypoglycemia (30           
minutes, 1-hour, 2-hours, 4-hours and 24-hours) for controls (white circles) and for T2D (black              
squares). At baseline, blood sugar (BS) was 7.5 ± 0.4 mM (for T2D) and 5.0 ± 0.1 (for control,                   
C). At point of hypoglycemia, blood sugar (BS) was 2.0 ± 0.03 mM (for T2D) and 1.8 ± 0.05                   
(for control). Proteomic (Somalogic) analysis of amyloid-related proteins was undertaken for           
Amyloid-precursor protein [APP] (A), Alpha-synuclein [SNCA] (B). Statistics: [ (* p< 0.05 or             
** p< 0.01, control vs T2D); (# p<0.01, control baseline vs control hypoglycemia); ($ p<0.05               
T2D baseline vs T2D hypoglycemia);(#$ p<0.05 control hypoglycemia vs control          
post-hypoglycemia timepoints); (^ p<0.05 T2D hypoglycemia vs T2D post-hypoglycemia         
timepoints); (#% control baseline vs control post-hypoglycemia timepoints). RFU, relative          
fluorescent units. 
 
Figure 2. Comparison of Alzheimer-related proteins in plasma of before, during and after             
iatrogenic induction of hypoglycemia. ​Blood sampling was performed at baseline, at           
hypoglycemia and post-hypoglycemia (30 minutes, 1-hour, 2-hours, 4-hours and 24-hours) for           
controls (white circles) and for T2D (black squares). At baseline, blood sugar (BS) was 7.5 ± 0.4                 
mM (for T2D) and 5.0 ± 0.1 (for control, C). At point of hypoglycemia, blood sugar (BS) was                  
2.0 ± 0.03 mM (for T2D) and 1.8 ± 0.05 (for control). Proteomic (Somalogic) analysis of                
amyloid-related proteins was undertaken for Microtubule-associated protein tau [MAPT] (A),          




0.05 control vs T2D); (# p<0.01, control baseline vs control hypoglycemia); ($ p<0.05 T2D              
baseline vs T2D hypoglycemia); (#$, p<0.05 control hypoglycemia vs control          
post-hypoglycemia timepoints); (^ p<0.05 T2D hypoglycemia vs T2D post-hypoglycemia         
timepoints). RFU, relative fluorescent units. 
 
Figure 3. Comparison of Alzheimer-related proteins in plasma of before, during and after             
iatrogenic induction of hypoglycemia. ​Blood sampling was performed at baseline, at           
hypoglycemia and post-hypoglycemia (30 minutes, 1-hour, 2-hours, 4-hours and 24-hours) for           
controls (white circles) and for T2D (black squares). At baseline, blood sugar (BS) was 7.5 ± 0.4                 
mM (for T2D) and 5.0 ± 0.1 (for control, C). At point of hypoglycemia, blood sugar (BS) was                  
2.0 ± 0.03 mM (for T2D) and 1.8 ± 0.05 (for control). Proteomic (Somalogic) analysis of                
amyloid-related proteins was undertaken for Serum amyloid A1 [SAA1]) (A), Apolipoprotein           
A1 (APOA1) (B), Apolipoprotein E3 (APOE3) (C) and Apolipoprotein E4 (APOE4) (D).            
Statistics: * p<0.05 control vs T2D). RFU, relative fluorescent units. 
 
Figure 4. ​STRING interaction network​. STRING version 11.0 interaction network showing the            
interactions of APCS, APP, SAA1 and APOA1 (A), MAPT and APP (B) and PAPPA (C). 
STRING 11.0 (Search Tool for the Retrieval of Interacting Genes) was used to visualize the               
known and predicted Protein-Protein Interactions for proteins identified by SOMAscan assay in            
plasma of T2D versus control subjects (​https://string-db.org/​). Network nodes represent          
proteins and the lines reflect physical and/or functional interactions of proteins. Empty nodes             




proteins with some three-dimensional structure, either known or predicted. Different colored           
lines between the proteins represent the various types of interaction evidence in STRING             
(databases, experiments, neighborhood, gene fusion, co-occurrence, text mining,        
co-expression, and homology). 
 
Figure 5. Ingenuity pathway analysis. ​Ingenuity pathway analysis of four amyloid-related           
protein genes (Amyloid P component [APCS], Amyloid precursor protein [APP], Pappalysin           
[PAPPA] and Serum amyloid A1 [SAA1]. 
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